Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

In this video, I will explain why Hims & Hers Health (NYSE: HIMS) crashed over 30% on Monday. Watch the short video to learn more, consider subscribing, and click the special offer link below. *Stock ...

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

It’s not often that investors come across the kind of companies that can yield a multi-bagger investment over the years.

Herb Greenberg, 'Herb on the Street' author, joins 'Power Lunch' to discuss Greenberg's thoughts on the terminated partnership between Novo Nordisk and Hims & Hers.

The Novo Nordisk partnership ending does not alter my long-term bullish thesis on HIMS; the company is much more than just a ...

Novo Nordisk ends Wegovy deal with Hims over legal issues, sending the stock tumbling. What happens next? Here's a look.

Hims & Hers Health, a telehealth company, offers direct-to-patient platform to distribute prescription drugs and OTC ...

Hims & Hers fell by 34.63 percent on Monday to close at $41.98 apiece after Novo Nordisk terminated its marketing partnership ...